Cardinal Health reported fiscal fourth-quarter revenue of $63.7 billion, up 6% from $60.2 billion a year earlier. Non-GAAP diluted earnings per share rose 40% to $2.91, against a consensus of $2.42. GAAP diluted EPS rose to $1.70 from $1.00. Guidance for fiscal 2027 is $12.40 to $12.60 of non-GAAP EPS, implying 13–15% growth over the $11.26 delivered in fiscal 2026.
The stock closed up 1.30% at $240.26.
The quarter
| Metric | Q4 FY2026 | Year ago |
|---|---|---|
| Revenue | $63.7B | $60.2B (+6%) |
| Non-GAAP EPS | $2.91 | $2.08 (+40%) |
| Consensus EPS | $2.42 | |
| GAAP EPS | $1.70 | $1.00 |
| FY2026 non-GAAP EPS | $11.26 | |
| FY2027 guidance | $12.40–$12.60 | +13–15% |
Sixty-three billion in, a rounding error out
Run the ratio. Quarterly revenue of $63.7 billion produces GAAP earnings measured in hundreds of millions. Operating margins in pharmaceutical distribution sit well under 1%.
That is not a flaw in the business, it is the business. Cardinal does not buy medicine and mark it up in any meaningful sense; it operates the logistics network that moves manufacturers' products to pharmacies and hospitals, and takes a fraction of a percent for doing it reliably at national scale.
Two consequences follow, and they are the whole investment case:
The first is that small changes in spread produce large changes in earnings. A model with a 0.5% margin turns a 10 basis point improvement into a 20% earnings move. That is why EPS grew 40% on 6% revenue growth, and it is why this stock's earnings are far more volatile than its revenue implies.
The second is that the moat is unusually hard. Rebuilding a distribution network with this density, at these margins, would take a decade and would not pay for itself. The barrier is not technology or brand — it is the fact that nobody sane would want the job at this price.
Where the growth is actually coming from
Distribution volume alone does not produce 13–15% earnings guidance. The uplift is coming from the higher-margin end of the portfolio: specialty pharmaceuticals, the services wrapped around them, and continued cost discipline in the core network.
Specialty is the part of healthcare where drug prices are highest and handling requirements are strictest, which means the fee for moving the product is larger in both absolute and percentage terms. Mix shift toward specialty is the mechanism converting a 6% top line into 40% adjusted earnings growth, and it is a mix shift with years left to run.
How I read it
This is one of the least exciting businesses in the S&P 500 and one of the more reliable compounding engines in it.
The FY2027 guide of $12.40–$12.60 is the anchor for any valuation work here. Growth of 13–15% from a defensive, non-cyclical earnings stream is what investors normally pay a premium multiple for; distributors rarely receive one, which is where the opportunity sits.
The risk is regulatory rather than operational. Drug pricing policy sets the fee pool this industry divides, and it changes by legislation, not by competition. That is the tail risk in every distributor, it does not show up in any quarter, and it is the reason the multiple stays low even when the earnings do not.